Trump has begun another trade war. Here's a timeline of how we got here
Canada's leader laments lost friendship with US in town that sheltered stranded Americans after 9/11
Chinese EV giant BYD's fourth-quarter profit leaps 73%
You're an American in another land? Prepare to talk about the why and how of Trump 2.0
Chalk talk: Star power, top teams and No. 5 seeds headline the women's March Madness Sweet 16
Purdue returns to Sweet 16 with 76-62 win over McNeese in March Madness
"Ozempic" has become shorthand for a new class of injectable diabetes and weight loss drugs flooding social media and dominating conversations. But use of the brand name overlooks meaningful distinctions between Ozempic and its sister drugs Wegovy, Mounjaro and Zepbound. Understanding the nuanced differences in approval, dosing, mechanisms and results can empower patients to make informed choices about these potentially life-changing medications.
Ozempic (semaglutide) was first approved by the FDA in 2017 for managing type 2 diabetes at doses of 0.5mg and 1mg, and received approval for a 2mg dose in 2022. Critically, it is not approved for weight loss purposes. Wegovy (also semaglutide), meanwhile, was greenlit by the FDA in 2022 specifically for chronic weight management at a higher once-weekly 2.4mg dose. Both utilize semaglutide, an injectable drug that stimulates GLP-1 receptors to reduce appetite and slow stomach emptying.
But some key differences exist between the two drugs beyond their FDA-approved uses. Wegovy is administered via disposable pen injectors, while Ozempic uses reusable multi-dose pens. And Wegovy's higher semaglutide dose has been associated with increased weight loss. In a 68-week trial, Wegovy patients lost 15% of body weight on average, likely attributable to the stronger 2.4mg dosage.
Experts cannot definitively state whether Ozempic confers the same degree of weight loss benefits as Wegovy, since it lacks FDA approval for that purpose. But its impacts on appetite at approved diabetes doses suggests potential weight management effects. More research is needed to clarify Ozempic's weight-related outcomes.
Both medications may cause side effects like nausea, vomiting, diarrhea and low blood sugar. They also carry warnings about potential thyroid tumor risks. Ongoing monitoring has not conclusively identified increased thyroid cancer rates, but vigilance is urged.
Mounjaro and Zepbound represent a new wave of dual-acting drugs employing tirzepatide to influence both GIP and GLP-1 receptors. Mounjaro was approved for type 2 diabetes in 2022, while the newly approved Zepbound is indicated specifically for weight management in obese patients, similar to Wegovy.
The key difference between Mounjaro and Zepbound lies in their brand names only - the drug formula is identical. But tirzepatide has a distinct mechanism from semaglutide. Activating both GIP and GLP-1 receptors appears to enhance glucose control and weight loss effects compared to GLP-1 drugs alone.
In trials, tirzepatide helped patients lose up to 26% of body weight over 72 weeks - significantly higher than semaglutide results. Mounjaro dosing also extends to 15mg weekly, the highest dose among these medications. Like semaglutide drugs, tirzepatide is well-tolerated but may cause GI issues.
With manifold options now available, the critical question becomes: which medication is right for specific patients' needs? No definitive answer exists, as choice depends heavily on patients' clinical profiles and insurance coverage. But some key principles can help inform decisions.
First and foremost, patients should consult their primary care doctor before pursuing these drugs. Providers can best evaluate if patients meet BMI and related health criteria for a prescription. Referral to nutritionists or weight loss specialists may provide additional guidance.
For diabetes management, Ozempic and Mounjaro are go-to choices given their FDA approval for that indication. Those without diabetes will be steered toward Wegovy or newly approved Zepbound. Insurance will also play a major role in determining accessible options.
If multiple drugs are viable options, providers may consider trial data showing greater average weight loss with semaglutide. But superior tolerance of tirzepatide could make it preferable for some patients. Regular monitoring and follow-up is key to tailoring medication plans.
Above all, these drugs are not quick fixes. They work best alongside lifestyle changes in diet and exercise habits. But used judiciously under medical supervision, they can be invaluable tools providing hope to many struggling with obesity or diabetes. Patients should understand the nuanced profiles of each medication, have open discussions with their doctors, and make choices aligned with their health needs and circumstances.
